Pancreatic neuroendocrine neoplasms (pNENs) are a rare form of pancreatic tumors. The most recent classification of these tumors was completed by the World Heath Organization in 2010 and subdivides the pNENs into three groups: NET G1, NET G2, and neuroendocrine carcinoma (NEC) based on proliferation rate. However, each individual classification includes a wide range of the tumors and does not further classify based on genetic background, whether the tumor is a primary tumor or it is metastasized, and tumor differentiation. By staining human tissue samples with antibodies, I will be able to highlight the cellular, stromal and nuclear parts of the cell. Using this information, I hope to identify proteins that come from mutant genes and better classify the tumors. The ultimate goal is to be able to link mutations to biomarkers in order to determine based on the mutations the best course of treatment for patients.